Fundraising Fox

Step Pharma

Saint-Genis-Pouilly, FR · 5 known investors

step-ph.com ↗

Step Pharma develops dencatistat (STP938), a first-in-class, orally bioavailable CTPS1 inhibitor in clinical development as a targeted oncology therapy for blood cancers such as lymphoma and essential thrombocythaemia as well as solid tumours including ovarian cancer. The company focuses on CTPS1 inhibition for cancer treatment.

BiotechDeep TechMedical Devices

Investors · 5

Hadean VenturesOslo
Kurma PartnersParis · $162K – $10.8M
Pontifax Venture CapitalHerzeliya · $6.3M – $128M
Sunstone CapitalFrederiksberg
V-Bio VenturesGhent · $270K – $2.2M

In the news

Step Pharma announces completion of €38 million Series C financing - BioSpacebiospace.com · Oct 2025Step Pharma Surges Ahead with €38 Million Series C Funding - Investors Hangoutinvestorshangout.com · Oct 2025About Us - Step Pharmastep-ph.com · Jul 2022Step Pharma raises funds through series B round to advance cancer drugspharmaceutical-technology.com · Mar 2021Step Pharma Raises EUR35 Million in Series B Financing to Advance First in Class CTPS1 inhibitor into the Clinic in T Cell Malignancies - Step Pharmastep-ph.com · Mar 2021Pontifax et al. in €14.5m round for Step Pharma | Unquoteunquote.com · Nov 2017

Frequently asked questions

What does Step Pharma do?
Step Pharma develops dencatistat (STP938), a first-in-class, orally bioavailable CTPS1 inhibitor in clinical development as a targeted oncology therapy for blood cancers such as lymphoma and essential thrombocythaemia as well as solid tumours including ovarian cancer. The company focuses on CTPS1 inhibition for cancer treatment.
Who are Step Pharma's investors?
Step Pharma's investors include Hadean Ventures, Kurma Partners, Pontifax Venture Capital, Sunstone Capital, V-Bio Ventures.
Where is Step Pharma headquartered?
Step Pharma is headquartered in Saint-Genis-Pouilly, FR.